All In Biotech

Drug Trial Radar · NCT07712536

Phase IIa Study of Pharmacokinetics, Safety and Efficacy of QY201 Tablets in Adolescent Subjects With Moderate to Severe Atopic Dermatitis

Last checked: Nov 19, 2026Latest source record: Jul 17, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

24

Actual

Start

Jun 4, 2025

Primary completion

Dec 19, 2025

Study completion Dec 19, 2025

Sponsor

Sponsor type
Industry
First posted
Jul 17, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 12 years, up to 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

To evaluate the population pharmacokinetic characteristics of QY201 Tablets in adolescent participants with moderate to severe atopic dermatitis (AD).

Conditions

  • Adolescent Participants With Moderate to Severe Atopic Dermatitis (AD)

Interventions

  • QY201 Tablets(10mg)Drug

    10 mg twice daily for 28 consecutive days

  • QY201 Tablets(20mg)Drug

    20 mg twice daily for 28 consecutive days

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Plasma concentrations of QY201 at multiple time points; population pharmacokinetic (PopPK) profiles of QY201Time frame: Day29

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Hangzhou First People's Hospital

    Hangzhou, Zhejiang, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.